2-(6-methylpyridin-2-yl)-N-pyridin-4-ylquinazolin-4-amine
Star0
Identification
- Generic Name
- 2-(6-methylpyridin-2-yl)-N-pyridin-4-ylquinazolin-4-amine
- DrugBank Accession Number
- DB07267
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 313.3559
Monoisotopic: 313.132745505 - Chemical Formula
- C19H15N5
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UTGF-beta receptor type-1 Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as pyridinylpyrimidines. These are compounds containing a pyridinylpyrimidine skeleton, which consists of a pyridine linked (not fused) to a pyrimidine by a bond.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazines
- Sub Class
- Pyrimidines and pyrimidine derivatives
- Direct Parent
- Pyridinylpyrimidines
- Alternative Parents
- Quinazolinamines / Methylpyridines / Aminopyrimidines and derivatives / Aminopyridines and derivatives / Imidolactams / Benzenoids / Heteroaromatic compounds / Secondary amines / Azacyclic compounds / Organopnictogen compounds show 1 more
- Substituents
- Amine / Aminopyridine / Aminopyrimidine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Diazanaphthalene / Heteroaromatic compound / Hydrocarbon derivative / Imidolactam show 9 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
- InChI Key
- JONFDFIXMPXTRH-UHFFFAOYSA-N
- InChI
- InChI=1S/C19H15N5/c1-13-5-4-8-17(21-13)19-23-16-7-3-2-6-15(16)18(24-19)22-14-9-11-20-12-10-14/h2-12H,1H3,(H,20,22,23,24)
- IUPAC Name
- 2-(6-methylpyridin-2-yl)-N-(pyridin-4-yl)quinazolin-4-amine
- SMILES
- CC1=CC=CC(=N1)C1=NC(NC2=CC=NC=C2)=C2C=CC=CC2=N1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 10267580
- PubChem Substance
- 99443738
- ChemSpider
- 8443059
- BindingDB
- 50293516
- ChEBI
- 143120
- ChEMBL
- CHEMBL570533
- ZINC
- ZINC000038440844
- PDBe Ligand
- 855
- PDB Entries
- 3hmm
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0129 mg/mL ALOGPS logP 3.62 ALOGPS logP 3.83 Chemaxon logS -4.4 ALOGPS pKa (Strongest Acidic) 15.03 Chemaxon pKa (Strongest Basic) 6.18 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 63.59 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 102.92 m3·mol-1 Chemaxon Polarizability 34.25 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9377 Caco-2 permeable + 0.6677 P-glycoprotein substrate Non-substrate 0.6308 P-glycoprotein inhibitor I Non-inhibitor 0.868 P-glycoprotein inhibitor II Non-inhibitor 0.8526 Renal organic cation transporter Non-inhibitor 0.839 CYP450 2C9 substrate Non-substrate 0.7926 CYP450 2D6 substrate Non-substrate 0.8725 CYP450 3A4 substrate Non-substrate 0.6995 CYP450 1A2 substrate Inhibitor 0.9664 CYP450 2C9 inhibitor Non-inhibitor 0.968 CYP450 2D6 inhibitor Non-inhibitor 0.9563 CYP450 2C19 inhibitor Non-inhibitor 0.8469 CYP450 3A4 inhibitor Inhibitor 0.6765 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.7265 Ames test AMES toxic 0.9313 Carcinogenicity Non-carcinogens 0.9079 Biodegradation Not ready biodegradable 0.9958 Rat acute toxicity 2.0268 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9629 hERG inhibition (predictor II) Non-inhibitor 0.8122
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0005-2962000000-932b25f29fda540461ad Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-03di-0009000000-5bdf551541658f746958 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-03di-0009000000-95c6a41282562ca7de9b Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-03di-0009000000-d7d415b1e108c169fe9e Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-03di-0039000000-b2e5f507b2fd9d0e4567 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0mbj-0290000000-bbeda9edff8c693e214a Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-00dj-0090000000-b2aa3375d265dbeac32c Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 168.83415 predictedDeepCCS 1.0 (2019) [M+H]+ 171.19217 predictedDeepCCS 1.0 (2019) [M+Na]+ 177.52513 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsTGF-beta receptor type-1
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Type ii transforming growth factor beta receptor binding
- Specific Function
- Transmembrane serine/threonine kinase forming with the TGF-beta type II serine/threonine kinase receptor, TGFBR2, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Tra...
- Gene Name
- TGFBR1
- Uniprot ID
- P36897
- Uniprot Name
- TGF-beta receptor type-1
- Molecular Weight
- 55959.18 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Drug created at September 15, 2010 21:19 / Updated at June 12, 2020 16:52